Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,078
archived clinical trials in
Major Depression Disorder (MDD)

This is a Study to Determine the Antidepressant Effects of AZD6765
An Investigation of the Antidepressant Effects of an NMDA Antagonist in Treatment-Resistant Major Depression
Status: Archived
Clinical Research Facility
mi
from
Baltimore, MD
This is a Study to Determine the Antidepressant Effects of AZD6765
An Investigation of the Antidepressant Effects of an NMDA Antagonist in Treatment-Resistant Major Depression
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Baltimore, MD
Stress Reduction Intervention for Enhancing Treatment Outcome for Depressed Minority Patients
Feasibility and Efficacy of a Stress Reduction Intervention for Enhancing Treatment Outcome for Depressed Minority Patients
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Stress Reduction Intervention for Enhancing Treatment Outcome for Depressed Minority Patients
Feasibility and Efficacy of a Stress Reduction Intervention for Enhancing Treatment Outcome for Depressed Minority Patients
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Forest Investigative Site 055
mi
from
Dothan, AL
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Forest Investigative Site 055
mi
from
Dothan, AL
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Forest Investigative Site 065
mi
from
Highlands Ranch, CO
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Forest Investigative Site 065
mi
from
Highlands Ranch, CO
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Forest Investigative Site
mi
from
Boca Raton, FL
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Forest Investigative Site
mi
from
Boca Raton, FL
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Forest Investigative Site 057
mi
from
Boca Raton, FL
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Forest Investigative Site 057
mi
from
Boca Raton, FL
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Forest Investigative Site 064
mi
from
Gainesville, FL
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Forest Investigative Site 064
mi
from
Gainesville, FL
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Forest Investigative Site 053
mi
from
Ocala, FL
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Forest Investigative Site 053
mi
from
Ocala, FL
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Multiple Sclerosis Institute
mi
from
Philadelphia, PA
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Multiple Sclerosis Institute
mi
from
Philadelphia, PA
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Forest Investigative Site 059
mi
from
Winter Park, FL
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Forest Investigative Site 059
mi
from
Winter Park, FL
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Forest Investigative Site
mi
from
Atlanta, GA
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Forest Investigative Site
mi
from
Atlanta, GA
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Forest Investigative Site 066
mi
from
Smyrna, GA
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Forest Investigative Site 066
mi
from
Smyrna, GA
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Forest Investigative Site 072
mi
from
Chicago, IL
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Forest Investigative Site 072
mi
from
Chicago, IL
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Medical Oncology and Hematology
mi
from
Waterbury, CT
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Medical Oncology and Hematology
mi
from
Waterbury, CT
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Forest Investigative Site 063
mi
from
Indianapolis, IN
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Forest Investigative Site 063
mi
from
Indianapolis, IN
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
The Hospital of Central Connecticut at New Britain General
mi
from
New Britain, CT
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
The Hospital of Central Connecticut at New Britain General
mi
from
New Britain, CT
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Forest Investigative Site 052
mi
from
Shreveport, LA
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Forest Investigative Site 052
mi
from
Shreveport, LA
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Forest Investigative Site 051
mi
from
Brooklyn, NY
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Forest Investigative Site 051
mi
from
Brooklyn, NY
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Forest Investigative Site 056
mi
from
Oklahoma City, OK
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Forest Investigative Site 056
mi
from
Oklahoma City, OK
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Forest Investigative Site 058
mi
from
Salem, OR
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Forest Investigative Site 058
mi
from
Salem, OR
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Forest Investigative Site 054
mi
from
Allentown, PA
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Forest Investigative Site 054
mi
from
Allentown, PA
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Forest Investigative Site 062
mi
from
San Antonio, TX
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Forest Investigative Site 062
mi
from
San Antonio, TX
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Forest Investigative Site 068
mi
from
Virginia Beach, VA
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Forest Investigative Site 068
mi
from
Virginia Beach, VA
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Forest Investigative Site 069
mi
from
Spokane, WA
Safety and Efficacy of F2695 SR in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Forest Investigative Site 069
mi
from
Spokane, WA
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Pfizer Investigational Site
mi
from
Fayetteville, AR
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Fayetteville, AR
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Pfizer Investigational Site
mi
from
Los Angeles, CA
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Los Angeles, CA
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Pfizer Investigational Site
mi
from
Arvada, CO
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Arvada, CO
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Pfizer Investigational Site
mi
from
Bridgeport, CT
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Bridgeport, CT
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Raleigh Regional Cancer Center
mi
from
Beckley, WV
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Updated: 1/1/1970
Raleigh Regional Cancer Center
mi
from
Beckley, WV
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Pfizer Investigational Site
mi
from
Atlanta, GA
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Atlanta, GA
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Pfizer Investigational Site
mi
from
Bloomingdale, IL
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Bloomingdale, IL
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Pfizer Investigational Site
mi
from
Avon, IN
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Avon, IN
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Pfizer Investigational Site
mi
from
Arkansas City, KA
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Arkansas City, KA
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Pfizer Investigational Site
mi
from
Bossier City, LA
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Bossier City, LA
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Darien Pediatric Associates
mi
from
Darien, CT
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Updated: 1/1/1970
Darien Pediatric Associates
mi
from
Darien, CT
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Pfizer Investigational Site
mi
from
Cape Girardeau, MO
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Cape Girardeau, MO
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Pfizer Investigational Site
mi
from
Clifton, NJ
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Clifton, NJ
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Pfizer Investigational Site
mi
from
Akron, OH
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Akron, OH
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Pfizer Investigational Site
mi
from
Norman, OK
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Norman, OK
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Pfizer Investigational Site
mi
from
Ashland, OR
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Ashland, OR
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Fletcher Allen Health Care
mi
from
Burlington, VT
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Updated: 1/1/1970
Fletcher Allen Health Care
mi
from
Burlington, VT
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Pfizer Investigational Site
mi
from
Cranston, RI
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Cranston, RI
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Pfizer Investigational Site
mi
from
Anderson, SC
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Anderson, SC
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Pfizer Investigational Site
mi
from
Houston, TX
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Houston, TX
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Pfizer Investigational Site
mi
from
West Jordan, UT
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
West Jordan, UT
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Pfizer Investigational Site
mi
from
Burke, VA
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Burke, VA
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Pfizer Investigational Site
mi
from
Madison, WI
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Madison, WI
Pilot Study of Open-label Placebo to Treat Major Depressive Disorder
Harnessing the Placebo Effect in Major Depressive Disorder
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Pilot Study of Open-label Placebo to Treat Major Depressive Disorder
Harnessing the Placebo Effect in Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder
An 8-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy and Safety of Agomelatine 0.5 mg and 1 mg Sublingual Tablets Administered Once Daily in Patients With Major Depressive Disorder (MDD)
Status: Archived
Birmingham Psychiatry
mi
from
Birmingham, AL
Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder
An 8-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy and Safety of Agomelatine 0.5 mg and 1 mg Sublingual Tablets Administered Once Daily in Patients With Major Depressive Disorder (MDD)
Status: Archived
Updated: 1/1/1970
Birmingham Psychiatry
mi
from
Birmingham, AL